Lecanemab
Bruyère Health welcomes the recent approval of Lecanemab
(brand name Leqembi®) by Health Canada—the first treatment in Canada shown to
slow the progression of early-stage Alzheimer’s disease by targeting its
underlying biology and slowing down the progression of dementia. This marks a
significant milestone in dementia care and offers new hope to individuals and
families affected by the disease who will now have the opportunity to weigh the
benefits and risks associated with this new treatment. To learn more
about this treatment, eligibility, and considerations, we encourage you to
review the attached handout from the Alzheimer’s Society of Canada.
If you have a disability and would like information in a different format, please ask us. We will work with you to create the format that’s best for you. Please send your request to communications@bruyere.org or call 613-562-6262.
You can also listen to a recent media interview with Dr. Andrew Frank, researcher and physician with the Bruyère Health Memory Clinic on how Lecanemab works, the risks, and when and how it will be accessible to Canadians.